Project Grant R01HL185125
Award Date 7/15/26
Completion Date 3/31/31
Dollars Obligated $724K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40506, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $538,808 to The University of Kentucky Research Foundation on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a five-year project extending through June 30, 2030. The project investigates the role of plasma membrane rupture (PMR) of pyroptotic macrophages in thrombosis and develops therapeutic approaches to prevent blood clot formation. Rather than targeting...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Trustees of Columbia University in the City of New York a Project Grant of $246,750 under the Cardiovascular Diseases Research program (CFDA 93.837) to support mechanistic research on CAV1.2 calcium channel dysregulation in hypertension. The research, which commenced July 15, 2026 and will conclude June 30, 2028, investigates how abnormal calcium channel function contributes to elevated blood...
- Federal Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $774,997 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through May 31, 2029. The award funds research investigating the contribution of medullary pre-sympathetic neurons to breathing disorders and autonomic dysfunction in heart failure with preserved ejection fraction...
- Federal Project Grant Award Summary Emory University received a $156,080 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded March 13, 2026, with completion targeted for September 11, 2027. The grant supports research investigating HEG1 (Heart of Glass 1) as a regulator of hypertension and atherosclerosis, addressing a critical gap in understanding the molecular and cellular mechanisms underlying these...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Arkansas a $546,654 Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) effective May 1, 2026 through January 31, 2030 to develop computational and experimental platforms for predicting and controlling cardiac fibrosis in heart failure with reduced ejection fraction (HFrEF) patients. The project integrates systems mechanobiology modeling with patient-derived cardiac...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $150,104 to the Regents of the University of Colorado (University of Colorado-Denver) on January 26, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The project, titled "Lysine Myristoylation as a Novel Mechanism for Regulating PKA in the Heart," will be completed by December 31, 2028. The research investigates an alternative mechanism to activate protein kinase A (PKA)...
- Federal Grant Award Summary Wake Forest University Health Sciences received a $881,454 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2026, with completion expected March 31, 2031. The grant supports the SUPERHERO (Study of the Epidemiology of Pediatric Hypertension) Registry, which will establish standardized methods to harmonize and analyze longitudinal data from 45,000 youth across...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of California, Los Angeles a $1.56 million Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective July 15, 2026, with completion targeted for March 31, 2028. This award funds basic science research to elucidate the role of noncoding RNA—specifically long noncoding RNAs (lncRNAs) and micropeptides—in cardiovascular disease pathogenesis, with emphasis on lipid metabolism,...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $694,723 to the University of Nevada, Reno under the Cardiovascular Diseases Research program (CFDA 93.837) for a four-year project commencing September 1, 2025 and concluding June 30, 2029. The research project will investigate the regulation of capillary blood flow through thin-stranded pericytes, specialized perivascular cells located in the microvasculature. The research deliverables include...
- Federal Project Grant Award Summary The University of Arizona received a $650,419 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2026, with completion targeted for March 31, 2030. The award funds research to develop a comprehensive mechanistic understanding of sarcomeric protein interactions and their role in hypertrophic cardiomyopathy (HCM). The research extends the investigator's...